Financial forecasting models and Wall Street price target estimates for DexCom (DXCM) project a steady upward trajectory through 2026, driven by continuous expansion in the global continuous glucose monitoring market. Depending on the specific quantitative model or institutional research desk, average price targets range widely, with certain algorithmic forecasters anticipating considerable percentage gains from historical trading levels as diabetes technology adoption accelerates. Analysts emphasize that sustaining these valuation goals depends heavily on the company's ability to maintain high profit margins, protect market share against medical device competitors, and execute successful international product rollouts.